Arvinas (ARVN) Amortization of Deferred Charges (2021 - 2026)
Arvinas' (ARVN) quarterly Amortization of Deferred Charges came in at $400000.0 in Q1 2026, down 33.33% year-on-year from $600000.0 in Q1 2025, and down 20.0% quarter-over-quarter from $500000.0 in Q4 2025.
Arvinas (ARVN) Amortization of Deferred Charges (2021 - 2026) Analysis & Trends
Arvinas' Amortization of Deferred Charges history runs 6 years deep, the most recent figure standing at $400000.0 for Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges fell 33.33% year-over-year to $400000.0 in Q1 2026; TTM through Mar 2026 was $2.0 million, a 4.76% decrease from a year earlier, with the FY2025 full-year figure at $2.2 million, up 10.0% from the prior year.
- Amortization of Deferred Charges eased to $400000.0 in Q1 2026 per ARVN's latest filing, from $500000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $600000.0 in Q1 2022 and bottomed at $400000.0 in Q2 2022.
- The 5-year median for Amortization of Deferred Charges is $500000.0 (2022), against an average of $494117.6.
- Across the five-year window, Amortization of Deferred Charges jumped 100.0% in 2022 and sank 33.33% in 2026, its largest moves.
- Year by year, Amortization of Deferred Charges stood at $400000.0 in 2022, then grew by 25.0% to $500000.0 in 2023, then changed by 0.0% to $500000.0 in 2024, then changed by 0.0% to $500000.0 in 2025, then dropped by 20.0% to $400000.0 in 2026.
- Per Business Quant, the three latest ARVN Amortization of Deferred Charges figures stand at $400000.0 (Q1 2026), $500000.0 (Q4 2025), and $500000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.84 Bn | 467.05 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn |
| 10 | Arvinas | 530.56 Mn | -84.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 400,000.00 |
| Mar 31, 2026 | 400,000.00 |
| Dec 31, 2025 | 500,000.00 |
| Dec 31, 2025 | 500,000.00 |
| Sep 30, 2025 | 500,000.00 |
| Sep 30, 2025 | 500,000.00 |
| Jun 30, 2025 | 600,000.00 |
| Jun 30, 2025 | 600,000.00 |
| Mar 31, 2025 | 600,000.00 |
| Mar 31, 2025 | 600,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Sep 30, 2024 | 500,000.00 |
| Sep 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Mar 31, 2024 | 500,000.00 |
| Mar 31, 2024 | 500,000.00 |
| Dec 31, 2023 | 500,000.00 |
| Dec 31, 2023 | 500,000.00 |